NCT02714569

A Study to Evaluate LY3202328 in Overweight Healthy Participants and Dyslipidemia

A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Oral Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY3202328

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Accepted

Summary

The purpose of this two-part study is to evaluate the safety and tolerability of the study drug known as LY3202328 in healthy overweight participants in Part A, and those with dyslipidemia (abnormal blood fats) in Part B.

Conditions

• Dyslipidemias

Interventions

Type	Name	Description
DRUG	LY3202328	Administered orally
DRUG	Placebo	Administered orally
DRUG	Atorvastatin	Administered orally
DRUG	Simvastatin	Administered orally

Timeline

• Start date: 2016-03-01
• Primary completion: 2017-02-15
• Completion: 2017-02-15
• First posted: 2016-03-21
• Last updated: 2021-05-25
• Results posted: 2021-05-25

Locations

4 sites across 1 country: United States